^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EFFECTS OF SELINEXOR ON PREVIOUSLY TREATED MULTIPLE MYELOMA (MM) WITH RAS-MUTATIONS
Published date:
05/12/2021
Excerpt:
In BOSTON, pts with RASmut MM treated with XVd had significantly longer progression-free survival (PFS) than those treated with Vd (median [med]=12.9 vs 6.7 months [mo], hazard ratio [HR]=0.48 [95% CI 0.24-0.97], p=0.039).
Secondary therapy:
bortezomib + dexamethasone
